Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies


  • Portions of this work were presented at the 2008 American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, CA.,USA.

Bruce J. Trock, Brady Urological Institute, Johns Hopkins School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287, USA. e-mail: btrock@jhmi.edu


Study Type – Diagnostic (exploratory cohort)

Level of Evidence 2b

What's known on the subject? and What does the study add?

Hypermethylation of genes such as glutathione-S-transferase P1 (GSTP1) and adenomatous polyposis coli (APC) occurs with high frequency in prostate tumour tissue but is much less common in the benign prostate; however, the potential value of gene methylation biomarkers as an adjunct to biopsy histopathology has had little study.

When measured in histologically benign prostate biopsy tissue, APC gene hypermethylation was found to have high negative predictive value and high sensitivity. GSTP1 hypermethylation was found to have lower performance than APC.


  • • To evaluate the performance of DNA methylation biomarkers in the setting of repeat biopsy in men with an initially negative prostate biopsy but a high index of suspicion for missed prostate cancer.


  • • We prospectively evaluated 86 men with an initial histologically negative prostate biopsy and high-risk features.
  • • All men underwent repeat 12-core ultrasonography-guided biopsy.
  • • DNA methylation of glutathione-S-transferase P1 (GSTP1) and adenomatous polyposis coli (APC) was determined using tissue from the initially negative biopsy and compared with histology of the repeat biopsy.
  • • The primary outcome was the relative negative predictive value (NPV) of APC compared with GSTP1, and its 95% confidence interval (CI).


  • • On repeat biopsy, 21/86 (24%) men had prostate cancer.
  • • APC and GSTP1 methylation ratios below the threshold (predicting no cancer) produced a NPV of 0.96 and 0.80, respectively. The relative NPV was 1.2 (95% CI: 1.06–1.36), indicating APC has significantly higher NPV.
  • • Methylation ratios above the threshold yielded a sensitivity of 0.95 for APC and 0.43 for GSTP1.
  • • Combining both methylation markers produced a performance similar to that of APC alone.
  • • APC methylation patterns were consistent with a possible field effect or occurrence early in carcinogenesis.


  • • APC methylation provided a very high NPV with a low percentage of false-negatives, in the first prospective study to evaluate performance of DNA methylation markers in a clinical cohort of men undergoing repeat biopsy.
  • • The potential of APC methylation to reduce unnecessary repeat biopsies warrants validation in a larger prospective cohort.